Henriette Golcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henriette Golcher has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Gerhard G. Grabenbauer
Department of Radiation Oncology of the University at Erlangen-Nuremberg, Erlangen, Germany
1 shared publication - Rolf Sauer
Department of Radiation Oncology of the University at Erlangen-Nuremberg, Erlangen, Germany
1 shared publication - Thomas Baptist Brunner
Universitätsklinik für Strahlentherapie-Radioonkologie, Medizinische Universität Graz, Graz, Österreich
1 shared publication - Thomas Meyer
Department of Surgery, University of Erlangen-Nuremberg, Germany
1 shared publication - Werner Hohenberger
Chirurgische Klinik, Universitätsklinikum Erlangen, Erlangen, Deutschland
1 shared publication
Latest Publications
- Open Access
- 6 March 2007
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 1-9
Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)
The disappointing results of surgical therapy alone of ductal pancreatic cancer can only be improved using multimodal approaches. In contrast to adjuvant therapy, neoadjuvant chemoradiation is able to facilitate resectability with free margins and to lower lymphatic spread. Another advantage is better tolerability which consecutively allows applying multimodal treatment in a higher number of patients. Furthermore, the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials. As there are no prospectively randomised studies for neoadjuvant therapy, the Interdisciplinary Study Group of Gastrointestinal Tumours of the German Cancer Aid has started such a trial. The study investigates the effect of neoadjuvant chemoradiation in locally resectable or probably resectable cancer of the pancreatic head without distant metastasis on median overall survival time compared to primary surgery. Adjuvant chemotherapy is integrated into both arms. The protocol of the study is presented in condensed form after an introducing survey on adjuvant and neoadjuvant therapy in pancreatic cancer.
- 6 March 2007
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 1-9
Open AccessPrimary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)
The disappointing results of surgical therapy alone of ductal pancreatic cancer can only be improved using multimodal approaches. In contrast to adjuvant therapy, neoadjuvant chemoradiation is able to facilitate resectability with free margins and to lower lymphatic spread. Another advantage is better tolerability which consecutively allows applying multimodal treatment in a higher number of patients. Furthermore, the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials. As there are no prospectively randomised studies for neoadjuvant therapy, the Interdisciplinary Study Group of Gastrointestinal Tumours of the German Cancer Aid has started such a trial. The study investigates the effect of neoadjuvant chemoradiation in locally resectable or probably resectable cancer of the pancreatic head without distant metastasis on median overall survival time compared to primary surgery. Adjuvant chemotherapy is integrated into both arms. The protocol of the study is presented in condensed form after an introducing survey on adjuvant and neoadjuvant therapy in pancreatic cancer.